Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach

Author:

Acramel Alexandre12ORCID,Blondeel‐Gomes Sandy3ORCID,Dupré Mathilde1,Kayembe Ornella Tangila1,Rochereau Aude1,Escalup Laurence1ORCID,Desmaris Romain1ORCID,Jourdan Nathalie4,Cordary Adeline5,Vaflard Pauline6ORCID,Cottu Paul67ORCID,Bellesoeur Audrey36ORCID

Affiliation:

1. Département de Pharmacie Institut Curie, PSL Research University Paris France

2. Université Paris Cité, CiTCoM, CNRS UMR 8038, Inserm U1268 Paris France

3. Département de Radiopharmacologie Institut Curie, PSL Research University Paris France

4. APHP, Hôpital Saint‐Louis, Pharmacie Paris France

5. Département de Qualité et Gestion des risques Institut Curie, PSL Research University Paris France

6. Département d'Oncologie médicale Institut Curie, PSL Research University Paris France

7. Université Paris Cité Paris France

Abstract

AimsThe purpose of this work was to assess failures in the advanced prescription of parenteral anticancer agents in an adult day oncology care unit with more than 100 patients per day.MethodsAn a priori descriptive analysis was carried out by using the risk matrix approach. After defining the scope in a multidisciplinary meeting, we determined at each step the failure modes (FMs), their effects (E) and their associated causes (C). A severity score (S) was assigned to all effects and a probability of occurrence (O) to all causes. These S and O indicators, were used to obtain a criticality index (CI) matrix. We assessed the risk control (RC) of each failure in order to define a residual criticality index (rCI) matrix.ResultsDuring risk analysis, 14 FMs were detected, and 61 scenarios were identified considering all possible effects and causes. Nine situations (15%) were highlighted with the maximum CI, 18 (30%) with a medium CI, and 34 (55%) with a negligible CI. Nevertheless, among all these critical situations, only three (5%) had an rCI to process (i.e., missed dose adjustment, multiple prescriptions and abnormal biology data); the others required monitoring only. Clinicians' and pharmacists' knowledge of these critical situations enables them to manage the associated risks.ConclusionsAdvanced prescription of injectable anticancer drugs appears to be a safe practice for patients when combined with risk management. The major risks identified concerned missed dose adjustment, prescription duplication and lack of consideration for abnormal biology data.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3